A Study of LY3549492 in Healthy Weight Adult Participants

Launched by ELI LILLY AND COMPANY · Jul 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called LY3549492 to see if it is safe and well-tolerated in adults who have a healthy body weight. Specifically, the study is looking at adults with a body mass index (BMI) between 22 and 25, which is considered a normal weight range. The trial will last about 13 months and is currently not recruiting participants yet.

To join the study, adults need to have had a stable weight for at least three months and meet the BMI range. People with certain health conditions, like type 1 diabetes, poorly controlled high blood pressure, recent heart problems, liver disease, or pancreatitis, would not be eligible. Also, those who have recently used medications or remedies for changing their weight cannot participate. If you qualify and take part, you can expect regular check-ups to monitor your health and how your body responds to the medication over the course of the study. This trial is focused on healthy adults to better understand the safety of LY3549492 before it is tested in other groups.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have a body mass index (BMI) within the range of 22 to 25 kilograms per square meter (kg/m2)
• • Have had a stable body weight for 3 months prior to screening
• Exclusion Criteria:
• • Have type 1 diabetes, latent autoimmune diabetes in adults, or a history of ketoacidosis or hyperosmolar coma
• * Have:
• • type 2 diabetes and on antidiabetic therapy (except type 2 diabetes being managed with diet and/or stable dose of metformin)
• • rare forms of diabetes mellitus, or
• • hemoglobin A1c (HbA1c) \>8%
• • Have poorly controlled hypertension
• * Have any of the following cardiovascular conditions within 12 months prior to screening:
• • acute myocardial infarction
• • stroke
• • unstable angina, or
• • hospitalization due to congestive heart failure.
• • Have a history of New York Heart Association Functional Classification III or IV congestive heart failure
• • Have signs and symptoms of liver disease
• • Have a history of pancreatitis
• • Have taken medications or alternative remedies for weight loss or weight gain within 3 months prior to screening